Market Price

4.43 

-0.06 -1.3%

as of May 17 '21

52 Week Range:

2.52 9.84


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) 23.41
28.52
58.19
62.58
74.93
80.24
87.60
87.88
75.74
35.39
33.11
growth rate 21.8% 104.0% 7.5% 19.7% 7.1% 9.2% 0.3% -13.8% -53.3% -6.4%
Earnings BIT -11.77
32.02
24.27
28.86
45.58
45.29
-9.78
112.45
94.79
-116.61
-86.55
growth rate 100.0% -24.2% 18.9% 57.9% -0.6% -100.0% 100.0% -15.7% -100.0% 0.0%
Avg.PE -103.10
31.25
6.47
74.07
82.71
144.00
84.77
-28.56
-28.56
15.52
0.95
growth rate 100.0% -79.3% 1,044.8% 11.7% 74.1% -41.1% -100.0% 0.0% 100.0% -93.9%
ROA -3.56
8.48
32.80
2.80
2.09
1.01
-2.82
-17.59
2.70
-26.00
-13.91
growth rate 100.0% 286.8% -91.5% -25.4% -51.7% -100.0% 0.0% 100.0% -100.0% 0.0%
ROE -8.16
17.17
52.43
3.98
3.60
1.93
-5.46
-37.72
5.95
-59.16
-36.30
growth rate 100.0% 205.4% -92.4% -9.6% -46.4% -100.0% 0.0% 100.0% -100.0% 0.0%
ROIC -6.29
18.02
51.07
4.10
3.57
2.29
-2.18
-22.05
5.10
-33.21
-13.47
growth rate 100.0% 183.4% -92.0% -12.9% -35.9% -100.0% 0.0% 100.0% -100.0% 0.0%
Cur. Ratio 3.30
4.13
3.37
3.80
3.58
4.98
1.84
3.07
3.77
2.33
1.61
growth rate 25.2% -18.4% 12.8% -5.8% 39.1% -63.1% 66.9% 22.8% -38.2% -30.9%
Quick Ratio 2.78
3.65
2.63
3.15
2.97
4.25
1.43
2.70
3.34
1.71
0.67
growth rate 31.3% -28.0% 19.8% -5.7% 43.1% -66.4% 88.8% 23.7% -48.8% -60.8%
Leverage 2.26
1.85
1.46
1.38
2.00
1.85
2.02
2.30
2.12
2.57
2.66
growth rate -18.1% -21.1% -5.5% 44.9% -7.5% 9.2% 13.9% -7.8% 21.2% 3.5%
Balance Sheet Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 22.30
22.83
61.42
50.10
32.21
31.47
52.24
81.40
23.43
22.08
20.19
growth rate 2.4% 169.1% -18.4% -35.7% -2.3% 66.0% 55.8% -71.2% -5.8% -8.6%
Acct.Payable 46.54
59.40
54.35
17.75
14.23
26.93
27.37
48.86
26.26
12.16
growth rate 27.6% -8.5% -67.3% -19.8% 89.2% 1.6% 78.5% -46.3% -53.7%
Cur.Assets 311.20
360.94
333.06
367.33
390.72
451.32
272.66
441.70
528.11
201.11
221.34
growth rate 16.0% -7.7% 10.3% 6.4% 15.5% -39.6% 62.0% 19.6% -61.9% 10.1%
Total Assets 342.10
379.49
565.33
607.13
1,065.07
1,111.29
1,342.34
1,197.97
1,299.67
799.72
632.68
growth rate 10.9% 49.0% 7.4% 75.4% 4.3% 20.8% -10.8% 8.5% -38.5% -20.9%
Cash 34.60
58.26
42.26
48.31
182.17
153.20
158.54
307.07
293.56
62.09
71.37
growth rate 68.4% -27.5% 14.3% 277.1% -15.9% 3.5% 93.7% -4.4% -78.9% 15.0%
Inventory 38.40
28.38
20.96
26.17
26.84
36.48
43.14
37.50
29.01
25.22
28.68
growth rate -26.1% -26.2% 24.9% 2.5% 35.9% 18.3% -13.1% -22.6% -13.1% 13.7%
Cur.Liabilities 94.20
87.34
98.87
96.64
114.38
90.59
147.90
143.96
140.26
86.39
137.25
growth rate -7.3% 13.2% -2.3% 18.4% -20.8% 63.3% -2.7% -2.6% -38.4% 58.9%
Liabilities 190.80
174.28
179.41
166.77
524.81
508.27
678.12
677.98
687.68
488.90
394.73
growth rate -8.7% 2.9% -7.0% 214.7% -3.2% 33.4% 0.0% 1.4% -28.9% -19.3%
LT Debt 6.60
6.26
4.57
3.23
289.88
291.53
324.03
334.48
343.14
218.27
166.17
growth rate -5.2% -27.0% -29.4% 8,880.3% 0.6% 11.2% 3.2% 2.6% -36.4% -23.9%
Equity 151.30
205.21
385.92
440.35
540.26
603.03
664.21
519.99
611.98
310.82
237.96
growth rate 35.6% 88.1% 14.1% 22.7% 11.6% 10.2% -21.7% 17.7% -49.2% -23.4%
Common Shares 6.00
7.00
7.00
7.00
7.00
7.00
8.00
8.00
8.00
8.00
8.00
growth rate 16.7% 0.0% 0.0% 0.0% 0.0% 14.3% 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 2.40
2.19
10.38
4.04
5.08
5.92
6.19
13.69
33.33
90.43
4.39
growth rate -8.7% 373.7% -61.1% 25.8% 16.5% 4.6% 121.1% 143.5% 171.3% -95.2%
Cash Dividends 0.00 0.00 0.00
growth rate
Cash From OA -19.22
66.34
52.12
39.29
74.65
38.48
29.65
97.14
150.79
-128.17
-61.01
growth rate 100.0% -21.4% -24.6% 90.0% -48.5% -23.0% 227.6% 55.2% -100.0% 0.0%
FCF per Share -4.44
4.99
5.73
2.99
10.75
-63.11
-33.29
7.57
25.07
-27.33
-11.58
growth rate 100.0% 14.8% -47.8% 259.5% -100.0% 0.0% 100.0% 231.2% -100.0% 0.0%
Sale Purchase of Stock 3.96
4.34
12.79
16.02
18.10
75.52
10.48
growth rate 9.5% 194.7% 25.3% 13.0% 317.3% -86.1%
FCF -29.00
61.00
39.00
25.00
-409.00
31.00
-238.00
82.00
117.00
-219.00
-65.00
growth rate 100.0% -36.1% -35.9% -100.0% 100.0% -100.0% 100.0% 42.7% -100.0% 0.0%
Income Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 191.00
292.24
305.81
336.43
401.48
492.66
519.60
588.29
471.43
192.41
152.97
growth rate 53.0% 4.7% 10.0% 19.3% 22.7% 5.5% 13.2% -19.9% -59.2% -20.5%
Op.Income -8.40
30.61
154.96
16.44
45.58
45.29
-9.78
112.45
94.79
-116.61
-86.55
growth rate 100.0% 406.3% -89.4% 177.3% -0.6% -100.0% 100.0% -15.7% -100.0% 0.0%
IBT -11.80
32.02
24.27
28.86
28.01
19.37
-42.27
-251.89
20.42
-274.25
-107.67
growth rate 100.0% -24.2% 18.9% -3.0% -30.9% -100.0% 0.0% 100.0% -100.0% 0.0%
Net Income -11.80
30.61
154.96
16.44
17.67
11.06
-34.62
-223.36
33.68
-272.97
-99.59
growth rate 100.0% 406.3% -89.4% 7.5% -37.4% -100.0% 0.0% 100.0% -100.0% 0.0%
EPS -1.86
4.56
23.04
2.34
2.52
1.50
-4.56
-29.16
4.26
-34.43
-12.32
growth rate 100.0% 405.3% -89.8% 7.7% -40.5% -100.0% 0.0% 100.0% -100.0% 0.0%
Gross Profit 154.80
225.67
248.17
269.79
320.87
399.73
411.49
476.33
373.79
98.88
96.79
growth rate 45.8% 10.0% 8.7% 18.9% 24.6% 2.9% 15.8% -21.5% -73.6% -2.1%
R&D 30.60
42.11
53.88
53.88
73.47
149.21
203.44
160.61
105.18
60.08
23.01
growth rate 37.6% 28.0% 0.0% 36.4% 103.1% 36.3% -21.1% -34.5% -42.9% -61.7%

Quarterly Statements

Item Name Dec '19 Mar '20 Jun '20 Jul '20 Dec '20
Earnings BIT 14.49
-32.25
-12.44
-12.44
-17.23
growth rate -100.0% 0.0% 0.0% 0.0%
Balance Sheet Dec '19 Mar '20 Jun '20 Jul '20 Dec '20
Acct.Receivable 22.08
14.97
14.77
13.39
20.19
growth rate -32.2% -1.3% -9.4% 50.9%
Acct.Payable 26.26
12.07
14.63
10.36
12.16
growth rate -54.0% 21.2% -29.2% 17.3%
Cur.Assets 201.11
168.29
158.02
151.81
221.34
growth rate -16.3% -6.1% -3.9% 45.8%
Total Assets 799.72
753.83
728.21
710.45
632.68
growth rate -5.7% -3.4% -2.4% -11.0%
Cash 62.09
32.42
57.91
57.91
71.37
growth rate -47.8% 78.6% 0.0% 23.2%
Inventory 25.22
25.57
32.94
30.12
28.68
growth rate 1.4% 28.8% -8.6% -4.8%
Cur.Liabilities 86.39
70.63
138.75
138.75
137.25
growth rate -18.2% 96.5% 0.0% -1.1%
Liabilities 891.01
447.15
437.30
396.92
394.73
growth rate -49.8% -2.2% -9.2% -0.6%
LT Debt 218.27
220.06
161.60
161.60
166.17
growth rate 0.8% -26.6% 0.0% 2.8%
Equity 310.82
306.67
313.53
313.53
237.96
growth rate -1.3% 2.2% 0.0% -24.1%
Common Shares 0.05
0.05
0.05
0.05
0.01
growth rate 0.0% 0.0% 0.0% -81.3%
Cash Flow Statement Dec '19 Mar '20 Jun '20 Jul '20 Dec '20
Capital Expenditures 14.01
2.25
-0.15
-0.15
0.32
growth rate -84.0% -100.0% 0.0% 100.0%
Cash Dividends
growth rate
Cash From OA -11.43
-38.78
-2.91
-2.91
1.45
growth rate 0.0% 0.0% 0.0% 100.0%
Sale Purchase of Stock
growth rate
FCF -25.44
-41.02
-3.05
-3.05
1.13
growth rate 0.0% 0.0% 0.0% 100.0%
Income Statement Dec '19 Mar '20 Jun '20 Jul '20 Dec '20
Sales 100.02
28.10
53.09
53.09
38.16
growth rate -71.9% 88.9% 0.0% -28.1%
Op.Income 14.49
-32.25
-12.44
-12.44
-17.23
growth rate -100.0% 0.0% 0.0% 0.0%
IBT 64.86
-13.47
8.81
8.81
-86.16
growth rate -100.0% 100.0% 0.0% -100.0%
Net Income 65.66
-6.47
7.35
7.35
-83.05
growth rate -100.0% 100.0% 0.0% -100.0%
EPS
growth rate
Gross Profit 41.83
24.26
35.19
35.19
23.34
growth rate -42.0% 45.1% 0.0% -33.7%
R&D 9.02
7.71
5.73
5.73
4.32
growth rate -14.6% -25.7% 0.0% -24.5%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (7.03)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 0.95 0.72 -0.98
EPS / Growth 16.5% 6.13 29.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 15.5% 15.5%
Future PE 0.01 0.64 10.64
Future EPS 6.77 25.85 25.85
Value Price
MOS %
0.02
-99.6%
4.07
-8.1%
68.00
1,434.9%
MOS Price 0.01 2.03 34.00
IRT 0.00 0.00 0.00

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.